Yuanmai Cell is registered in Jiangbei New Area, Nanjing, and was jointly established by the research team led by Shen Pingping from Nanjing University and senior executives of pharmaceutical enterprises. The Company focuses on the development of treatment technologies for fibrotic diseases and solid tumors, committed to addressing unmet clinical needs. Currently, it has built four core technology platforms with independent intellectual property rights, namely the anti-fibrotic Payloads high-throughput screening system, the CAR functional module library, the in vitro gene editing system, and the in vivo gene editing delivery system. By leveraging in vivo gene editing delivery technology, Yuanmai Cell advances macrophage engineering technology from in vitro transfection to in vivo editing, realizing a leap from cell therapy to biopharmaceuticals. Its project targeting liver fibrotic diseases has already initiated Investigator-Initiated Trials (IITs).

Professor Shen Pingping, the scientific founder of the Company, was selected into the "New Century Excellent Talents Support Program" of the Ministry of Education. She currently serves as a professor at the School of Life Sciences, Nanjing University, and holds the position of Principal Investigator (PI) at the Research Center of Nanjing Drum Tower Hospital under the State Key Laboratory of Pharmaceutical Biotechnology. Under Professor Shen’s leadership, her research team has achieved remarkable results. In recent years, the team has received funding from multiple programs, including the National Key R&D Program, the Innovative Research Team of the National Natural Science Foundation of China (NSFC), the Major Research Program of NSFC, the "New Century Excellent Talents Support Program" of the Ministry of Education, and major frontier technology projects of Jiangsu Province. As the first completed person, Professor Shen has also won many awards, such as the first prize of Jiangsu Provincial Science and Technology Award in 2014 and the "Outstanding Achievement Award" at the 12th World Congress on Advances in Oncology. Professor Shen’s team has long been engaged in research on "macrophage immune regulation and related immunotherapy technologies" and has achieved a series of original results.

Yuanmai Cell is a typical project of university sci-tech achievement transformation. The investment decision on Yuanmai Cell fully demonstrates the key driving role of government-guided funds in fostering new productive forces. It effectively accelerates the transformation of university sci-tech achievements into practical productive forces, promotes the accurate alignment of cutting-edge university technologies with market demands, further enhances the agglomeration and influence of Nanjing in the gene and cell therapy industry chain, and lays a solid foundation for the high-quality development of Nanjing’s biopharmaceutical industry.